Last moves
Peptide Exchange
0molecules on your watchlist

Incretins

Tirzepatide

Brand Mounjaro and Zepbound

Lilly's weekly dual incretin peptide, sold as Mounjaro and Zepbound. Third quarter 2026 sales reached about 16.1 billion dollars, roughly two thirds of Lilly's revenue, and the FDA added a cardiovascular risk reduction claim in type 2 diabetes.

Tirzepatide comes from Eli Lilly and sits in the Incretins class on the board. Route: weekly injection. Use tracked here: Type 2 diabetes and chronic weight management, with a new US cardiovascular risk reduction claim in type 2 diabetes. It stands at Approved on the board, with 2 news moves logged; the latest is dated 30 Oct 2026.

  1. 05ApprovedHere now
  2. 04FiledApplication submitted to a regulator and under review.
  3. 03Phase 3Large confirmatory trials meant to support a filing.
  4. 02Phase 2Does it work at all, and at which dose? Hundreds of patients.
  5. 01Phase 1First doses in people. Safety, dose range, how the body handles it.
Company
Eli Lilly
Mechanism
Dual GIP and GLP 1 receptor agonist peptide
Given as
weekly injection
Lead use on the board
Type 2 diabetes and chronic weight management, with a new US cardiovascular risk reduction claim in type 2 diabetes
Moves logged
2latest 4 days ago

Tirzepatide news moves

  1. ▲ ExplainerHolds APP

    Tirzepatide sales drive a Lilly guidance raise as Mounjaro grows 65 percent

    Mounjaro and Zepbound brought in about 16.1 billion dollars in the third quarter, and Lilly lifted its 2026 revenue range to 91 to 92 billion dollars. Tirzepatide stays approved on the board, with lower prices and pill rivals as the open questions.

  2. ■ ExplainerNo stage

    GLP1R gene variant tied to more weight loss and more nausea on GLP 1 drugs

    A 23andMe Research Institute study of 27,885 GLP-1 users links a GLP1R variant to a small extra weight loss and more nausea, and a GIPR variant to vomiting on tirzepatide only. Genes explained little of the spread, and no test is in clinical use.